A family with autosomal dominant hypocalcaemia with hypercalciuria (ADHH): mutational analysis, phenotypic variability and treatment challenges.
Autosomal dominant hypocalcaemia with hypercalciuria (ADHH) is an intriguing syndrome, in which activating mutations of the calcium sensing receptor (CaSR) have recently been recognised. We describe a kindred with seven affected individuals across three generations, including patients affected in th...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2005
|
| _version_ | 1797071234215706624 |
|---|---|
| author | Burren, C Curley, A Christie, P Rodda, C Thakker, R |
| author_facet | Burren, C Curley, A Christie, P Rodda, C Thakker, R |
| author_sort | Burren, C |
| collection | OXFORD |
| description | Autosomal dominant hypocalcaemia with hypercalciuria (ADHH) is an intriguing syndrome, in which activating mutations of the calcium sensing receptor (CaSR) have recently been recognised. We describe a kindred with seven affected individuals across three generations, including patients affected in the first decade of life. Age at diagnosis varied from birth to 50 years. Affected members had hypocalcaemia (1.53-1.85 mmol/l), hypercalciuria, low but detectable parathyroid hormone (PTH) and hypomagnesaemia. Four of seven affected individuals were symptomatic (seizures, abdominal pains and paraesthesias), unrelated to severity of hypocalcaemia. Additional complications include nephrocalcinosis (n = 3) and basal ganglia calcification, identified by CT scanning in all five individuals. Symptomatic individuals were treated with calcium and calcitriol to reduce the risk of hypocalcaemic seizures. DNA sequence analysis, identified a mutation in exon 3, codon 129 (TGC-->TAC) of the CaSR gene of seven affected family members, resulting in loss of a conserved cysteine residue, potentially disrupting CaSR receptor dimerisation. Thus, a novel mutation was identified in this family, who demonstrate variability of ADHH phenotype and also illustrate the complexities of clinical management. Optimal management of ADHH is difficult and we recommend judicious treatment to avoid an increased risk of nephrocalcinosis. |
| first_indexed | 2024-03-06T22:50:20Z |
| format | Journal article |
| id | oxford-uuid:5e8f6493-fa6f-46d9-a860-de5a6827cb5c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:50:20Z |
| publishDate | 2005 |
| record_format | dspace |
| spelling | oxford-uuid:5e8f6493-fa6f-46d9-a860-de5a6827cb5c2022-03-26T17:41:27ZA family with autosomal dominant hypocalcaemia with hypercalciuria (ADHH): mutational analysis, phenotypic variability and treatment challenges.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:5e8f6493-fa6f-46d9-a860-de5a6827cb5cEnglishSymplectic Elements at Oxford2005Burren, CCurley, AChristie, PRodda, CThakker, RAutosomal dominant hypocalcaemia with hypercalciuria (ADHH) is an intriguing syndrome, in which activating mutations of the calcium sensing receptor (CaSR) have recently been recognised. We describe a kindred with seven affected individuals across three generations, including patients affected in the first decade of life. Age at diagnosis varied from birth to 50 years. Affected members had hypocalcaemia (1.53-1.85 mmol/l), hypercalciuria, low but detectable parathyroid hormone (PTH) and hypomagnesaemia. Four of seven affected individuals were symptomatic (seizures, abdominal pains and paraesthesias), unrelated to severity of hypocalcaemia. Additional complications include nephrocalcinosis (n = 3) and basal ganglia calcification, identified by CT scanning in all five individuals. Symptomatic individuals were treated with calcium and calcitriol to reduce the risk of hypocalcaemic seizures. DNA sequence analysis, identified a mutation in exon 3, codon 129 (TGC-->TAC) of the CaSR gene of seven affected family members, resulting in loss of a conserved cysteine residue, potentially disrupting CaSR receptor dimerisation. Thus, a novel mutation was identified in this family, who demonstrate variability of ADHH phenotype and also illustrate the complexities of clinical management. Optimal management of ADHH is difficult and we recommend judicious treatment to avoid an increased risk of nephrocalcinosis. |
| spellingShingle | Burren, C Curley, A Christie, P Rodda, C Thakker, R A family with autosomal dominant hypocalcaemia with hypercalciuria (ADHH): mutational analysis, phenotypic variability and treatment challenges. |
| title | A family with autosomal dominant hypocalcaemia with hypercalciuria (ADHH): mutational analysis, phenotypic variability and treatment challenges. |
| title_full | A family with autosomal dominant hypocalcaemia with hypercalciuria (ADHH): mutational analysis, phenotypic variability and treatment challenges. |
| title_fullStr | A family with autosomal dominant hypocalcaemia with hypercalciuria (ADHH): mutational analysis, phenotypic variability and treatment challenges. |
| title_full_unstemmed | A family with autosomal dominant hypocalcaemia with hypercalciuria (ADHH): mutational analysis, phenotypic variability and treatment challenges. |
| title_short | A family with autosomal dominant hypocalcaemia with hypercalciuria (ADHH): mutational analysis, phenotypic variability and treatment challenges. |
| title_sort | family with autosomal dominant hypocalcaemia with hypercalciuria adhh mutational analysis phenotypic variability and treatment challenges |
| work_keys_str_mv | AT burrenc afamilywithautosomaldominanthypocalcaemiawithhypercalciuriaadhhmutationalanalysisphenotypicvariabilityandtreatmentchallenges AT curleya afamilywithautosomaldominanthypocalcaemiawithhypercalciuriaadhhmutationalanalysisphenotypicvariabilityandtreatmentchallenges AT christiep afamilywithautosomaldominanthypocalcaemiawithhypercalciuriaadhhmutationalanalysisphenotypicvariabilityandtreatmentchallenges AT roddac afamilywithautosomaldominanthypocalcaemiawithhypercalciuriaadhhmutationalanalysisphenotypicvariabilityandtreatmentchallenges AT thakkerr afamilywithautosomaldominanthypocalcaemiawithhypercalciuriaadhhmutationalanalysisphenotypicvariabilityandtreatmentchallenges AT burrenc familywithautosomaldominanthypocalcaemiawithhypercalciuriaadhhmutationalanalysisphenotypicvariabilityandtreatmentchallenges AT curleya familywithautosomaldominanthypocalcaemiawithhypercalciuriaadhhmutationalanalysisphenotypicvariabilityandtreatmentchallenges AT christiep familywithautosomaldominanthypocalcaemiawithhypercalciuriaadhhmutationalanalysisphenotypicvariabilityandtreatmentchallenges AT roddac familywithautosomaldominanthypocalcaemiawithhypercalciuriaadhhmutationalanalysisphenotypicvariabilityandtreatmentchallenges AT thakkerr familywithautosomaldominanthypocalcaemiawithhypercalciuriaadhhmutationalanalysisphenotypicvariabilityandtreatmentchallenges |